[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100585088":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":11,"centralContacts":27,"locations":33,"responsibleParty":50,"collaborators":11,"id":52,"slug":11,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":11,"eligibilityCriteria":56,"healthyVolunteers":57,"sex":58,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":11,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":11,"overallStatus":70,"whyStopped":11,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"Zhejiang Wenda Pharma Technology LTD.","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"WD-910 Take a fixed dose of WD-910 tablets orally","EXPERIMENTAL",null,[13],"Drug: WD-910 tablet",{"label":15,"type":10,"description":11,"interventionNames":16},"WD-910 Tablets Placebo Take a fixed dose of WD-910 tablets Placebo orally",[17],"Drug: WD-910 Tablets Placebo",[19,24],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":11},"DRUG","WD-910 tablet","Administered P.O.",[9],{"type":20,"name":25,"description":22,"armGroupLabels":26,"otherNames":11},"WD-910 Tablets Placebo",[15],[28],{"name":29,"role":30,"phone":31,"phoneExt":11,"email":32},"Arockiaa Joseph","CONTACT","+61 459 661 281","c.trollip@nucleusnetwork.com.au",[34],{"facility":35,"status":11,"city":36,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"Nucleus Network Pty Ltd","Melbourne","Victoria","3004","Australia","AU",{"type":42,"coordinates":43},"Point",[44,45],144.96332,-37.814,{"lat":45,"lon":44},[48],{"name":49,"role":30,"phone":31,"phoneExt":11,"email":32},"Joseph",{"type":51,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100585088",false,"NCT06897813","A Phase I Randomised, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of WD-910 in Healthy Participants","Inclusion Criteria:\n\n* Aged 18 to 55 years (inclusive) at the time of informed consent.\n* Body mass index (BMI) between 18 to 32 kg\u002Fm2 and male participant with body weight of ≥ 50.0 kg, female participant with body weight ≥ 45.0 kg\n\nExclusion Criteria:\n\n* Any major surgery within 12 weeks prior to Day 1, or any planned surgery during the study.\n* Poor pill swallowing ability",true,"ALL","18 Years","55 Years",{"count":62,"type":63},68,"ESTIMATED","INTERVENTIONAL",[66],"PHASE1","This is a phase I, randomised, double-blind, placebo-controlled, 3-part study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and food effect of WD-910 in in Healthy Participants Detailed",[69],"Healthy Participants","NOT_YET_RECRUITING","2025-03-26",{"date":73,"type":74},"2025-04-02","ACTUAL",{"date":76,"type":63},"2025-06-30",{"date":78,"type":63},"2025-12-31",{"name":5,"class":6},1]